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Abstract
Background: Patients with hepatocellular carcinoma (HCC) beyond the Milan criteria are not considered
for liver transplantation (LT) in many centres; however, LT may be the only treatment able to achieve
long-term survival in patients with unresectable HCC. The aim of this study was to assess the role of
recipient age and tumour biology expressed by the DNA index in the selection of HCC patients for LT.
Patients: Clinicopathological data of 364 patients with HCC who underwent LT between 1989 and 2010
were evaluated. Overall survival (OS) was analysed by patient age, tumour burden based on Milan criteria
and the DNA index.
Results: After a median follow-up time of 78 months, the median survival was 100 months. Factors
associated with OS on univariate analysis included Milan criteria, patient age, hepatitis C infection,
alpha-fetoprotein (AFP) level, the DNA index, number of HCC, diameter of HCC, bilobar HCC,
microvascular tumour invasion and tumour grading. On multivariate analysis, HCC beyond Milan criteria
and the DNA index >1.5 independently predicted a worse OS. When stratifying patients by both age and
Milan criteria, patients ≤60 years with HCC beyond Milan criteria had an OS comparable to that of patients
>60 years within Milan criteria (10-year OS: 33% versus 37%, P = 0.08). Patients ≤60 years with HCC
beyond Milan criteria but a favourable DNA index ≤1.5 achieved excellent long-term outcomes, compa-
rable with those of patients within Milan criteria.
Conclusions: Patients ≤60 years may undergo LT for HCC with favourable outcomes independently of
their tumour burden. Additional assessment of tumour biology, e.g. using the DNA index, especially in this
subgroup of patients can support the selection of LT candidates who may derive the most long-term
survival benefit, even if Milan criteria are not fulfilled.
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Introduction
Since the implementation of the Milan criteria,1 liver transplan-
tation (LT) has been established as the preferred treatment for
patients with end-stage liver disease and hepatocellular carcinoma
(HCC) resulting in survivals comparable to those of LT recipients
with a benign disease. Recent studies showed that selected patients
with a HCC burden beyond Milan criteria may also achieve
favourable outcomes underlining the need for improvement of
the selection criteria for LT among HCC patients.2–5 Extended
criteria such as The University of California, San Francisco
(UCSF) criteria,6 the Tokyo criteria,7 the Asan criteria8 and the ‘up
to seven criteria’9 have been introduced with the aim of improving
the selection of appropriate liver transplant recipients among
patients with advanced HCC; however, such classifications
focused on morphological characteristics underestimating the
physical status and age of the patient or the tumour biology.
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Previous studies showed that patient age is associated with
overall survival (OS) after LT for HCC,10,11 or LT in general12–14 and
a cut-off age of >60 years11 or >65 years15 has been frequently
identified as a predictor of worse survival. This finding is also
confirmed by the long-term data of the European liver transplant
registry showing significantly better survivals for patients younger
than 60 years who were treated with LT in Europe between 1988
and 2011 (10-year OS rate: 66% for 15- to 45-year-old patients
versus 59% for 45- to 60-year-old patients versus 50% for >60-
year-old patients, P < 0.0001) (European Liver Transplant Regis-
try). The importance of patient age when evaluating LT candidates
is underlined by the fact that a significant number of patients who
undergo LT in Europe and the USA are older than 60 years.
According to the OPTN & SRTR Annual Data Report 2011, 64%
of patients who underwent LT in the USA in 2011 were between 50
and 64 years old and 13% of the patients were ≥65 years old.
Similarly, 37% of patients treated with LT in Europe in 2011 were
between 56 and 64 years old and 13% of the patients were ≥65
years old (Eurotransplant Annual Report 2011). The trend to trans-
plant patients older than 60 years has been increasing over the last
30 years, from <5% in the 1980s to 25% in 2011, and one-fourth
of these patients were suffering from cancer disease mainly HCC
being the primary disease leading to LT (European Liver Trans-
plant Registry).
In addition to the assessment of patient biology when evaluat-
ing LT candidates, tumour biology could play a decisive role in the
selection of patients with advanced HCC who may achieve favour-
able long-term survivals. Recent studies have described the DNA
index as an objective tool to express tumour biology. This tumour
marker is defined as the ratio of the DNA content of tumour cells
to the DNA content of the diploid reference cells and cut-off
values ≤1.5, ≤1.4 and ≤2 have been reported to be associated with
favourable biology and improved survivals after LT for HCC,16
liver resection for intrahepatic cholangiocarcinoma17 and resec-
tion of adenocarcinoma of the pancreatic head,18 respectively.
The objective of this study was to analyse the OS of patients
who underwent LT for HCC in a high-volume transplant centre
and identify factors associated with improved outcomes. We addi-
tionally aimed to assess the role of recipient age and tumour
biology in the selection of appropriate LT candidates beyond
tumour burden criteria.
Materials and methods
Patient inclusion criteria
After Institutional Review Board approval, clinicopathological
data of 364 consecutive patients with HCC who underwent LT
between 1989 and 2010 at the Charité Campus Virchow-Klinikum
in Berlin, Germany, were prospectively collected and reviewed.
Patients without a histological confirmation of HCC in the
explanted liver and patients with fibrolamellar HCC were
excluded from the study. Paediatric patients (<18 years) were not
included in the analysis.
Pre-operative assessment
The pre-operative assessment included medical history, physical
examination, serum laboratory tests, imaging studies and an
anaesthesia evaluation. Multiphase contrast-enhanced computed
tomography with liver protocol19 was used to define the extent and
location of HCC and to rule out macrovascular tumour invasion
and the presence of extrahepatic disease. The diagnosis was con-
firmed by one additional imaging method (magnetic resonance
imaging or ultrasonography) or percutaneous biopsy. Decision
making for listing patients for LT was based on case presentations
attended by liver transplant surgeons, transplant hepatologists
and radiologists.
Surgical procedure
Orthotopic LT was performed using a standardized approach with
inferior vena cava interposition or the piggyback technique.
Reperfusion was started after the completion of the end-to-end
anastomoses of the portal vein and the hepatic artery. Subse-
quently, venting was started via the inferior cava vein. The remain-
ing anastomoses were performed after haemostasis had been
achieved.20,21 Side-to-side choledochocholedochostomy was per-
formed, and a T-tube was placed in the common bile duct of the
recipient.22
Post-operative management
Post-operative mortality was defined as any in-hospital death after
LT, and post-operative morbidity was defined as any complication
within 90 days.
All specimens were histologically examined to confirm the
diagnosis of HCC, and evaluate the tumour grading. Pathological
specimens were also examined to identify microvascular invasion,
which was defined as gross or microscopic involvement of the
lobar or segmental branches of the portal or hepatic veins as well
as the presence of tumor emboli within the central hepatic vein,
the portal vein or the large capsular vessels.23 Remaining speci-
mens from the dominant HCC nodule were used for DNA
cytometry to assess the DNA index as previously described by our
group.16–18 A DNA index ≤1.5 was used to define favourable
tumour biology in this study as previously reported.16
Statistical analysis
Quantitative and qualitative variables were expressed as medians
(range) and frequencies. Comparisons between groups were ana-
lysed with the chi-square or Fisher’s exact test for categorical
variables and the Mann–Whitney U-test for continuous vari-
ables, as appropriate. Patients were stratified by their age and the
clinicopathological characteristics of patients 60 years old or
younger were compared with those of patients older than 60
years. Moreover, the relationship between the DNA index and
other surrogate factors for tumour biology was investigated. OS
was calculated from the date of LT to the date of death or last
follow-up using the Kaplan–Meier method. The recurrence rate
was also calculated from the date of LT to the date of first
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recurrence. Patients without recurrence were censored at the
date of last follow-up or patient death without tumour recur-
rence. Log-rank tests were used to assess significance for
univariate analyses.
To identify factors associated with OS of patients undergoing
LT for HCC, the following clinicopathological variables were rec-
orded and analysed: recipient gender (male versus female),
recipient age (≤60 versus >60 years), donor age (≤60 versus >60
years), donor gender (male versus female), hepatitis C infection
(yes versus no), Child–Pugh classification (A versus B and C),
alpha-fetoprotein level (AFP) (≤400 versus >400 ng/ml),
neoadjuvant treatment with transarterial chemoembolization
(TACE) (yes versus no), number of HCC (>3 versus ≤3), largest
diameter of HCC (>5 cm versus ≤5 cm), Milan criteria (beyond
versus within), bilobar HCC (yes versus no), DNA index (>1.5
versus ≤1.5), microvascular tumour invasion (yes versus no),
tumour grading (G1 and G2 versus G3), acute rejection (yes
versus no) and post-LT complications (yes versus no). All vari-
ables associated with survival with P < 0.05 in the univariate
analysis were subsequently entered into a Cox multivariate
regression model with backward elimination. P-values < 0.05
were considered statistically significant. Statistical analyses were
performed using the SPSS software package, version 20 (IBM,
Armonk, NY, USA).
Results
Patient characteristics
During the study period, 364 patients with HCC underwent LT.
Patient characteristics of the entire study cohort are summarized
in Table 1. The median age was 58 years (21–69), and 82% of the
patients were male. HCC burden fulfilled the Milan criteria in
59% of patients and 31% of patients had a DNA index >1.5.
Clinicopathological characteristics by patient age (≤60 versus >60
years) were also summarized in Table 1. Patients in both sub-
groups had comparable peri-operative and tumour characteris-
tics. No significant differences could be identified between the two
groups regarding the percentage of patients suffering from a
chronic hepatitis C infection or the degree of chronic liver disease
according to the Child–Pugh score. Neoadjuvant treatment with
TACE was performed independently from patient age. There was
also no association between patient age and the number of HCC,
diameter of HCC, tumour grading or the presence of
microvascular tumor invasion. Post-LT morbidity and mortality
did not significantly differ between patients ≤60 and patients >60
years old (P = 0.773 and P = 0.079, respectively). The two groups
were different in respect to the incidence of acute rejection after
LT which was higher among younger patients. However, this had
no impact on the rate of primary graft dysfunction and the need
for re-transplantation between the two groups.
Table 1 Clinicopathological characteristics of 364 patients who underwent liver transplantation for hepatocellular carcinoma (HCC)
Characteristics All patients
(n = 364)
Age ≤60 years
(n = 249)
Age >60 years
(n = 115)
Pa
Male gender, n (%) 297 (82) 206 (83) 91 (79) 0.410
Median donor age (range), years 50 (8–91) 49 (13–84) 52 (8–91) 0.265
Male donor, n (%) 207 (57) 147 (59) 60 (52) 0.193
Hepatitis C, n (%) 125 (34) 82 (33) 43 (37) 0.405
Median ischemia time (range), hours 10 (1–21) 9 (1–21) 10 (1–19) 0.124
Median ICU stay of donor(range), days 3 (0–25) 3 (0–25) 3 (0–23) 0.188
Child-Pugh class B/C, n (%) 207 (57) 147 (59) 60 (52) 0.239
Median AFP (range), ng/ml 16 (1–108195) 17 (1–108195) 15 (1–46100) 0.457
TACE, n (%) 97 (27) 61 (25) 36 (31) 0.172
Median number of HCC (range) 1 (1–12) 1 (1–12) 2 (1–10) 0.322
Median largest diameter of HCC (range), cm 3 (0.5–20) 3 (0.5–20) 3 (1–15) 0.099
Within Milan criteria, n (%) 214 (59) 150 (60) 64 (56) 0.408
Bilobar HCC, n (%) 94 (26) 60 (24) 34 (29) 0.358
Median DNA index (range) 1.2 (0.88–2.7) 1.3 (0.9–2.7) 1.2 (0.88–2.6) 0.372
Microvascular invasion, n (%) 118 (32) 82 (33) 36 (31) 0.798
Grading 3, n (%) 87 (24) 57 (23) 30 (26) 0.453
Acute rejection, n (%) 95 (26) 75 (30) 20 (17) 0.011
Median number of intraoperative transfusions (range) 4 (0–60) 4 (0–60) 2 (0–16) 0.004
Post-LT complications, n (%) 51 (14) 34 (14) 17 (15) 0.773
In-hospital mortality, n (%) 10 (2.7) 4 (1.6) 6 (5.2) 0.079
aComparison of patients ≤60 years with patients >60 years.
LT, liver transplantation; AFP, alpha-Fetoprotein; TACE, transarterial chemoembolization; ICU, intensive care unit.
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Association between the DNA index and surrogate
factors for tumour biology
The DNA index was significantly associated with AFP level
>400 ng/ml (P = 0.014), poor tumour differentiation (G3) (P =
0.026), largest diameter of HCC >5 cm (P = 0.041), number of
HCC >3 (P = 0.003) and microvascular invasion (P < 0.0001).
Long-term outcomes and predictors of OS
After a median follow-up time of 78 months (1–235), the median
survival of all patients who underwent LT for HCC (n = 364) was
100 months.
Univariate and multivariate analyses for predictors of OS in
HCC patients after LT are summarized in Table 2. On univariate
analysis, factors associated with worse OS included recipient age
>60 years (P < 0.0001), hepatitis C infection (P = 0.032), AFP level
>400 ng/ml (P = 0.004), number of HCC >3 cm (P < 0.0001),
diameter of the largest HCC >5 cm (P < 0.0001), HCC beyond
Milan criteria (P < 0.0001), bilobar HCC (P = 0.002), a DNA index
>1.5 (P < 0.0001), microvascular invasion (P < 0.0001) and
tumour grading G3 (P < 0.0001). The number of HCC and diam-
eter of the largest HCC were not included in the multivariate
analysis in order to avoid the effect of covariance. On multivariate
analysis, only HCC beyond Milan criteria [hazard ratio (HR) 1.69,
95% confidence interval (CI) 1.17–2.44, P = 0.005] and a DNA
index >1.5 (HR 4.22, 95% CI 2.89–6.17, P < 0.0001) were inde-
pendently associated with worse OS. Tumour recurrence was the
most frequent cause of death among patients with a DNA index
>1.5 (59%, P = 0.002). De novo malignancies were responsible for
12% of deaths in this subgroup, and the remaining 29% of
patients with a DNA index >1.5 died as a result of cardiovascular,
pulmonary or infectious complications.
When stratifying patients by both age and Milan criteria,
patients ≤60 years with HCC beyond Milan criteria had an OS
after 10 years comparable to that of older patients within Milan
criteria (33% versus 37%, P = 0.08; Fig. 1). Further assessment of
tumour biology using a DNA index for younger patients with
advanced disease showed that recipients ≤60 years old with HCC
beyond Milan criteria but a favourable DNA index ≤1.5 had excel-
lent OS (10-year OS rate 59%; Fig. 2), comparable to that of all
patients within Milan criteria.
Discussion
This study analysed the outcomes of patients with HCC who
underwent LT in a major transplant centre and indicated that
patient and tumour biology have a significant impact on OS.
Consequently, assessment of both patient age and DNA index may
support the selection of patients to undergo LT for HCC with
promising long-term results independently of the extent of their
tumour burden as this is described by the Milan criteria, or other
extended criteria.
Univariate analysis for predictors of OS in the study cohort
identified among other factors patient age, Milan criteria and
DNA index to be significantly associated with OS. On the mul-
tivariate analysis, HCC beyond Milan criteria and a DNA index
>1.5 independently predicted worse OS. Subsequent survival
analysis by stratifying patients by both age and Milan criteria
showed that patients ≤60 years old within Milan criteria had the
best OS (10-year OS rate 68%) whereas patients >60 years old
beyond Milan criteria had a significantly diminished 10-year
survival rate of only 6%. Interestingly, we could show that there
was no significant difference in 10-year survival between patients
≤60 years beyond Milan criteria and patients >60 years within
Milan criteria (33% versus 37%, P = 0.08), despite the tendency
for improved survival among older patients within Milan criteria
observed 5 years after LT, indicating that favourable patient
biology might counterbalance the negative effect of advanced
disease on long-term outcome. Evaluation of the risk for HCC
recurrence in our study cohort showed that patients >60 years
old with HCC within the Milan criteria had a lower risk for
tumour recurrence than patients ≤60 years old beyond Milan
criteria (Fig. 3). This confirms our hypothesis that younger
patients beyond Milan criteria may have comparable OS to older
patients within Milan criteria in spite of diverging recurrence
rates owing to the different co-morbidity profiles between the
two groups. Further assessment of tumour biology using the
DNA index in the subset of patients ≤60 years old with a HCC
burden beyond Milan criteria showed that if tumour biology
was favourable as defined by a DNA index ≤1.5 the OS was
excellent and comparable to the survival of patients who fulfilled
the Milan criteria.
Our study confirms previous studies showing that younger
patients may have significantly better long-term survivals after LT
for HCC than patients older than 60 years10,11 or 65 years.15 Based
on our findings, we do not intend to advocate the opinion that LT
should be denied to elderly patients within Milan criteria but
rather underline the need for more careful evaluation of younger
patients who may not be considered for LT if they do not fulfill the
Milan criteria. Decision making in such borderline cases can be
supported by the evaluation of tumour biology, e.g. using the
DNA index. The combination of less aggressive tumour biology
and younger age, which in many cases implies a better physical
status, less comorbidities, a better tolerance towards treatments
for eventual recurrence24–27 and a lower risk for the development
of de novo malignancies,28,29 may provide the most promising
probability for achieving prolonged OS after LT independently of
conventional criteria based on the number and size of tumour
nodules. Therefore, according to our selection algorithm for LT
(Fig. 4), we recommend a percutaneous biopsy from the domi-
nant lesion during the pre-operative evaluation of LT candidates
≤60 years with HCC beyond the Milan criteria but, e.g. within the
UCSF criteria to assess the DNA index. Patients with a DNA index
≤1.5 and favorable tumour biology could be considered for a
living-donor LT. The risk for tumour seeding after biopsy30 in
HCC patients is present but relatively low. However, we think that
the net benefit of examination of the biopsy with determination of
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Table 2 Univariate and multivariate analysis of clinicopathological variables associated with overall survival in 364 patients who underwent
liver transplantation for hepatocellular carcinoma (HCC)
Variable % Median survival
(months)
Univariate
analysis
Multivariate analysisa
P Hazard Ratio
(95% CI)
Recipient gender 0.492
Male 82 97
Female 18 130
Recipient age, years <0.0001 NS
≤60 68 147
>60 32 61
Donor age, years
≤60 73 108 0.570
>60 27 69
Donor gender 0.839
Male 57 105
Female 43 94
Hepatitis C 0.032 NS
Yes 34 74
No 66 132
Child–Pugh classification 0.297
A 43 96
B and C 57 125
AFP level 0.004 NS
>400 ng/ml 14 61
≤400 ng/ml 86 125
TACE 0.848
Yes 27 80
No 73 101
Number of HCC <0.0001
>3 16 36
≤3 84 125
Largest diameter of HCC <0.0001
>5 cm 18 40
≤5 cm 82 125
Milan criteria (histology) <0.0001 0.005
Beyond 41 44 1.69 (1.17–2.44)
Within 59 170
Bilobar HCC 0.002 NS
Yes 26 51
No 74 125
DNA index <0.0001 <0.0001
>1.5 30 27 4.22 (2.89–6.17)
≤1.5 70 176
Microvascular invasion <0.0001 NS
Yes 32 56
No 68 158
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the DNA index is still given, as it provides a valuable selection tool
for LT for patients with HCC beyond the Milan criteria.
Our present retrospective study has some limitations. The long
study period of 21 years may imply disparities in the surgical
technique and peri-operative management between the different
time periods. However, patient care under the guidance of trans-
plant surgeons with experience of more than 20 years in the field
and the large volume of patients being transplanted in our centre
every year have contributed to a consistent state-of-the-art patient
treatment over the entire study period. Another potential limita-
tion are the possible changes in the biological age and life expec-
tancy between the different time periods with an expected slower
progression of the biological age and an increase of life-
expectancy over the study period. However, the impact these
changes might have had on survival after LT has been possibly
counterbalanced by the concomitantly increasing number of
patients >60 years old undergoing LT in the most recent years. A
potential bias regarding the survival differences between the two
patient groups stratified by age (≤60 versus >60 years) might have
been related to the utilization of neoadjuvant treatment with
TACE. Nevertheless, our comparative analysis between the two
groups showed that since the implementation of this therapy,
patients with HCC on the waiting list were treated with TACE
before LT independently of their age.
In conclusion, this study indicates that patients 60 years old or
younger may undergo LT for HCC with favourable outcomes even
if they do not fulfill the very restrictive Milan criteria. Additional
assessment of tumour biology, e.g. using DNA cytometry, within
this subset of patients can contribute to the better selection of
Table 2 Continued
Variable % Median survival
(months)
Univariate
analysis
Multivariate analysisa
P Hazard Ratio
(95% CI)
Grading <0.0001 NS
G1 and G2 76 125
G3 24 51
Acute rejection 0.851
Yes 26 117
No 74 96
Post-LT complications 0.196
Yes 14 61
No 86 108
aCox regression multivariate analysis included all variables with P < 0.05 in univariate analysis.
CI, confidence interval; LT, liver transplantation; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization; NS, not significant.
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Figure 1 Overall survival (OS) according to age and Milan criteria
(MC) in 364 patients with hepatocellular carcinoma (HCC) who
underwent liver transplantation
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Figure 2 Overall survival (OS) according to the DNA index in 98
patients ≤60 years old with hepatocellular carcinoma (HCC) beyond
Milan criteria (MC) who underwent liver transplantation
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patients with HCC who may derive the most long-term survival
benefit from LT beyond Milan criteria.
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